LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

AZN

185.95

+2.31%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

AZN

185.95

+2.31%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

AZN

185.95

+2.31%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

AZN

185.95

+2.31%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

AZN

185.95

+2.31%↑

Kodu・Aktsiate loetelu・Merck & Co Inc.

Merck & Co Inc.

Suletud

SektorTervishoid

120.93 0.57

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

120.76

Max

121.63

Põhinäitajad
By Trading Economics
Sissetulek	-7.2B -4.2B
Müük	-114M 16B
P/E Sektori keskmine	32.442 49.888
Aktsiakasum	-1.28
Dividenditootlus	2.76
Kasumimarginaal	-26.053
Töötajad	73,000
EBITDA	-6.2B -1.9B

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+13.01% upside

Dividendid
By Dow Jones
Dividenditootlus Sektori keskmine	2.76% 2.38%
Järgmine tulemuste avaldamine	4. aug 2026
Järgmine dividendimakse kuupäev	8. juuli 2026
Järgmine aktsia dividendi kuupäev (ex-date)	15. juuni 2026

Turustatistika
By TradingEconomics
Turukapital	12B 284B
Eelmine avamishind	120.36
Eelmine sulgemishind	120.93

Uudiste sentiment

By Acuity

32%

68%

72 / 344 Pingereas Healthcare

Merck & Co Inc. Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

30. apr 2026, 14:20 UTC

Tulu

Merck 1Q Sales Rise on Continued Keytruda Growth -- Update

30. apr 2026, 10:45 UTC

Tulu

Merck 1Q Sales Rise on Continued Keytruda Growth

5. mai 2026, 18:12 UTC

Tulu

BioNTech to Slash 22% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

5. mai 2026, 13:54 UTC

Tulu

BioNTech to Slash 25% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

5. mai 2026, 12:48 UTC

Omandamised, ülevõtmised, äriostud

Merck Cites Costs Associated With Advancing TERN-701 and Financing >MRK

5. mai 2026, 12:48 UTC

Omandamised, ülevõtmised, äriostud

Merck: GAAP and Adj EPS Expected to Be Negatively Impacted by About 12c/Shr in 2026 >MRK

5. mai 2026, 12:47 UTC

Omandamised, ülevõtmised, äriostud

Merck: Transaction Expected to Be Accounted for as Asset Acquisition, Resulting in Chg of About $5.8 B, or $2.35/Shr, Included in 2Q and FY26 Results >MRK

5. mai 2026, 12:45 UTC

Omandamised, ülevõtmised, äriostud

Merck Completes Acquisition Of Terns Pharmaceuticals, Inc. >MRK TERN

1. mai 2026, 18:35 UTC

Tulu

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

1. mai 2026, 14:53 UTC

Tulu

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

30. apr 2026, 13:27 UTC

Tulu

Merck Stock Falls After Earnings. It's Working on Ways to Blunt Future Lost Keytruda Sales. -- Barrons.com

30. apr 2026, 10:47 UTC

Tulu

Update: Merck Stock Rises on Earnings. These Problems Loom Larger Than Keytruda Patent Cliff. -- Barrons.com

30. apr 2026, 10:30 UTC

Tulu

Merck: Also Anticipate EPS Will Be Negatively Affected by About 12c Over Remainder of 2026 Following Close of Terns Deal >MRK

30. apr 2026, 10:30 UTC

Tulu

Merck Raises 2026 View To Adj EPS $5.04-Adj EPS $5.16 Vs Prior View $5-$5.15 >MRK

30. apr 2026, 10:30 UTC

Tulu

Merck: 2026 Outlook Doesn't Reflect Any Impact From Proposed Acquisition of Terns Pharmaceuticals, Which Is Expected to Close in May and Result in One-Time Charge of About $2.35/Shr >MRK

30. apr 2026, 10:30 UTC

Tulu

Merck: Sales Outlook Includes Positive Impact From Forex of About 1% at Mid-April 2026 Exchange Rates >MRK

30. apr 2026, 10:30 UTC

Tulu

Merck: Adj EPS Outlook Also Reflects One-Time Charge of $3.62/Shr for Acquisition of Cidara >MRK

30. apr 2026, 10:30 UTC

Tulu

Merck: Adj EPS Outlook Includes Positive Impact From Forex of About 10c/Shr at Mid-April 2026 Exchange Rates >MRK

30. apr 2026, 10:30 UTC

Tulu

Merck Narrows 2026 View To Sales $65.8B-$67B Vs Prior View $65.5B-$67B >MRK

30. apr 2026, 10:30 UTC

Tulu

Merck: Latest 1Q Includes Charge of $3.62/Share for the Acquisition of Cidara >MRK

30. apr 2026, 10:30 UTC

Tulu

Merck: 1Q Gardasil/Gardasil 9 Sales Also Reflect Lower Sales in U.S. Primarily Due to Unfavorable Public-Sector Purchasing Patterns, Partially Offset by Higher Net Pricing >MRK

30. apr 2026, 10:30 UTC

Tulu

Merck 1Q Gardasil/Gardasil 9 Sales Down 19% >MRK

30. apr 2026, 10:30 UTC

Tulu

Merck: Lower 1Q Januvia/Janumet Sales Due to Lower Demand and Net Pricing in U.S., Lower Demand in China and Most Other International Markets Due to Generic Competition >MRK

30. apr 2026, 10:30 UTC

Tulu

Merck: Pleased With Progress and Excited for What's Ahead, as We Enter Particularly Robust Period of Phase 3 Data Readouts and Deliver on Promise of Our Pipeline for Patients >MRK

30. apr 2026, 10:30 UTC

Tulu

Merck 1Q Winrevair Sales $525M, Up 88%, Reflecting Continued Uptake in U.S. and Early Launch Uptake in Certain Intl Mkts, Especially Japan and Europe >MRK

30. apr 2026, 10:30 UTC

Tulu

Merck: 1Q Animal Health Sales Growth Attributable to Performance in Both Livestock and Companion Animal Product Portfolios >MRK

30. apr 2026, 10:30 UTC

Tulu

Merck: Lower 1Q Gardasil/Gardasil 9 Sales Primarily Due to Lower Demand in China as Well as Lower Sales in Japan Following National Catch-Up Immunization Program >MRK

30. apr 2026, 10:30 UTC

Tulu

Merck 1Q Pharmaceutical Sales Up 5% >MRK

30. apr 2026, 10:30 UTC

Tulu

Merck 1Q Animal Health Sales Up 13% >MRK

30. apr 2026, 10:30 UTC

Tulu

Merck 1Q Sales $16.29B >MRK

Võrdlus sarnastega

Hinnamuutus

Merck & Co Inc. Prognoos

Hinnasiht

By TipRanks

13.01% tõus

12 kuu keskmine prognoos

Keskmine 136.5 USD 13.01%

Kõrge 179 USD

Madal 112 USD

Põhineb 19 Wall Streeti analüütiku instrumendi Merck & Co Inc. 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

19 ratings

Osta

Hoia

Müü

Põhineb 19 analüütiku instrumendi Merck & Co Inc. aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

72 / 344 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.